Codexis, Inc. (NASDAQ:CDXS – Get Rating) Director John J. Nicols sold 35,714 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $4.09, for a total transaction of $146,070.26. Following the transaction, the director now owns 783,965 shares of the company’s stock, valued at approximately $3,206,416.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Codexis Stock Performance
Shares of CDXS stock traded down $0.23 during trading hours on Friday, hitting $3.89. 788,632 shares of the company were exchanged, compared to its average volume of 665,028. The firm has a market cap of $256.55 million, a P/E ratio of -7.63 and a beta of 1.64. Codexis, Inc. has a fifty-two week low of $3.86 and a fifty-two week high of $22.22. The company has a 50 day simple moving average of $5.55 and a two-hundred day simple moving average of $5.70.
Codexis (NASDAQ:CDXS – Get Rating) last announced its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. Codexis had a negative net margin of 24.24% and a negative return on equity of 21.78%. The company had revenue of $30.40 million during the quarter, compared to the consensus estimate of $28.92 million. During the same quarter last year, the firm posted ($0.16) EPS. The company’s quarterly revenue was up 24.1% on a year-over-year basis. As a group, sell-side analysts expect that Codexis, Inc. will post -0.89 EPS for the current fiscal year.
Institutional Trading of Codexis
Wall Street Analysts Forecast Growth
Several research firms have issued reports on CDXS. StockNews.com began coverage on shares of Codexis in a report on Thursday. They set a “hold” rating for the company. Piper Sandler raised their price objective on shares of Codexis from $22.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, January 19th. Finally, HC Wainwright reduced their price objective on shares of Codexis from $15.00 to $9.00 in a research report on Monday, February 27th.
Codexis Company Profile
Codexis, Inc is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market.
- Get a free copy of the StockNews.com research report on Codexis (CDXS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.